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A B S T R A C T
Increased platelet serotonin level (PSL) has been consistently found in a portion of autistic patients. Suggested mech-
anisms for hyperserotonemia in autism have been increased synthesis of serotonin (5HT) by tryptophan hydroxylase
(TPH), increased uptake into platelets through 5HT transporter (5HTt), diminished release from platelets through 5HT2A
receptor (5HT2Ar) and decreased metabolism by monoamine oxydase (MAOA). The allelic influence of genes, encoding
the mentioned 5HT elements, on PSL was investigated in 63 autistic subjects. Our study shows that 5HTt-LPR and
–1438AG 5HT2Ar genotypes did not significantly affect PSL. However, significantly higher PSLs were observed in sub-
jects with »cc« genotype of a218c TPH and subjects with »4« genotype of uVNTR MAOA. In addition, when TPH-cc and
MAOA-4 were combined as »high 5HT« genotypes, a correlative increase in PSL was observed with the increase in the
number of »high 5HT« genotypes. These results suggest a possible synergistic effect of genes regulating 5HT synthe-
sis/degradation in dysregulation of the peripheral 5HT homeostasis of autistic patients.
Key words: autism, hyperserotonemia, serotonin transporter, tryptophan hydroxylase, monoamine oxydase A, 5HT2A
receptor
Introduction
Autism is a neurodevelopmental syndrome character-
ized by disturbances in social interactions, language and
communication, as well as by the presence of stereotyped
behaviors and interests1. Prevalence of autism in general
population is 3–6 per 1,000 with a high recurrence risk of
2–8% in siblings of the diseased, and up to 92% in
monozygotic twins. This points to the strong genetic
component of this disorder2.
Several lines of evidence suggest that the alterations
in serotonergic neurotransmitter system might repre-
sent one of the biological substrates of the disease. Sero-
tonin (5-hydroxytryptamine, 5HT) has been shown to
play an important role in brain development by regulat-
ing both, serotonergic outgrowth and maturation of tar-
get regions3. Pharmacological manipulation of 5HT trans-
mission has been shown to influence some of the autistic
symptoms4–6, while positron emission tomography stud-
ies have demonstrated an altered brain 5HT synthesis
capacity of autistic children7,8. Perhaps the most intrigu-
ing 5HT-related finding in autistic disorder is hyper-
serotonemia. For several decades elevated blood 5HT lev-
els have been consistently found in about one third of the
autistic patients9, but the mechanism of the observed
phenomenon has remained unclear. Increased synthesis
of 5HT in the intestine10, increased uptake of serotonin
into platelets11, diminished release from platelets9, or de-
creased catabolism of 5HT12 have been suggested as pos-
sible causes.
More than 99% of the whole blood serotonin is con-
tained in platelets9. 5HT concentration in platelets, or
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the platelet serotonin level (PSL), is regulated by several
elements that control either the rate of 5HT synthesis
and metabolism (i.e. its concentration in blood plasma),
or the rate of its accumulation into- and release from the
platelets.
Tryptophan hydroxylase (TPH) is the rate limiting
enzyme of 5HT synthesis. The peripheral isoform is en-
coded by the gene Tph1 that contains a single nucleotide
polymorphism (SNP), adenine to cytosine transition on
the position 218 of the intron 7, termed a218c TPH13.
Monoamine oxydase A (MAOA) catalyzes oxidative
deamination of 5HT, an essential step in catabolism of
monoamines. Its gene contains a 30 bp variable number
of tandem repeats (VNTR) in the promoter (upstream)
region, termed uVNTR MAOA14. Although alleles with 2,
3, 3.5, 4, 4.5, 5 and 6 repeats have been reported, variants
with 3 and 4 repeats constitute more than 97% of the al-
leles in all reported control samples15.
Serotonin transporter (5HTt) and serotonin receptor
(5HT2Ar) are located on the platelet membrane. Seroto-
nin transporter actively transports 5HT from blood pla-
sma into the platelet. A 22 bp VNTR in the promoter re-
gion, termed 5HTt-LPR, results either in a 16-repeat
long (L) allele or in a 14-repeat short (S) allele16.
Activation of 5HT2A receptor mediates the release of
serotonin from the platelet in the process of platelet ag-
gregation. Analysis of the promoter region of the gene re-
vealed a SNP at the position –1438 that contains either
adenine or guanine17, termed –1438AG 5HT2Ar.
With the exception of a218c TPH, expression studies
suggested possible functional relevancies of the men-
tioned polymorphisms by showing allele-dependent dif-
ferences in the promoter activities of the corresponding
genes14,16,18.
All of the mentioned 5HT-regulating peripheral pro-
teins have their counterparts, encoded by the same ge-
nes, in the brain where they regulate 5HT neurotrans-
mission. It might be assumed that the alterations in their
expression could lead to hyperserotonemia in the periph-
ery with simultaneous dysregulation of 5HT transmis-
sion in the brain, the two phenomena observed in autis-
tic individuals. With this hypothesis in mind, we have
studied the potential influence of the allelic variants of
TPH, MAOA, 5HTt and 5HT2Ar genes on the platelet
5HT levels in a group of individuals affected with autism.
Subjects and Methods
Autistic patients were recruited from the Center for au-
tism Zagreb, Croatia, after being examined by a psychia-
trist and two psychologists. The group consisted of 63 sub-
jects (47 males, 16 females, X±SD:20.2±9.0) diagnosed
with autism spectrum disorders (54 with autism, 1 with
Aspereger’s syndrome, and 8 with PDD NOS), according to
DSM-IV criteria. Severity of behavioral symptoms was
measured using the Childhood Autism Rating Scale (CA-
RS)19. Degree of mental retardation was assessed according
to the standardized intelligence or developmental tests, de-
pending on the apparent developmental level of each indivi-
dual. Drug therapy included typical neuroleptics (7 pa-
tients), anticonvulsants (5 patients), and a combination of
neuroleptics and anticonvulsants (26 patients, 18 with typi-
cal and 8 with atypical neuroleptics).
All subjects were of Croatian origin. After an informa-
tive talk, a written consent for inclusion in the study was
obtained from the patients’ parents. The study has been
carried out in accord with the Declaration of Helsinki,
and was approved by the Ethics Committee of the Medi-
cal Faculty of the University of Zagreb.
Blood sampling was performed between 9 and 11 a.m.
Venous blood was collected into vacutainers containing
ACD (for PSL determination) or EDTA (for genotyping)
anticoagulants.
After a thorough mixing, blood was transferred to the
15 mL Falcon tubes and centrifuged at 1,050 × g for 2
minutes to obtain PRP. Separated PRP was aliquoted for
an automated determination of platelet number and vol-
ume, and for measurements of 5HT concentration (in du-
plicates).
Platelet pellet, obtained by centrifugation of a diluted
PRP sample (1 mL PRP + 3 mL saline) at 8,500 × g for 5
minutes, was sonicated in 1 mL of deionized water. Fol-
lowing deproteinisation with ZnSO4/NaOH, 5HT content
was measured by orthophtaldialdehyde-enhanced fluoro-
metry at 345/485 nm, as previously reported20. Results
were expressed as ng 5HT per mL of total platelet volume
(calculated as the product of mean platelet volume and
platelet count).
DNA was isolated from the whole blood using a DNA
isolation kit for mammalian blood (Boehringer Man-
heim, Germany).
PCR for 5HTt-LPR polymorphism was performed in a
total volume of 15 mL containing 1.5 mM MgCl2, 0.8 mM
dNTP mix (dATP, dCTP, dTTP, dGTP, 7-deaza-dGTP=
1:1:1:0.5:0.5), 0.5 mM primers (forward 5’-GGCGTT-
GCCGCTCTGAATGC-3’, reverse 5’-GAGGGACTGAGC-
TGGACAACCAC-3’), 0.5 U Taq polymerase, and 200 ng
template, with the addition of Q solution (Qiagen, Ger-
many). Cycling conditions consisted of a 5-min denatur-
ation at 95 °C, followed by 40 cycles of 30 s at 95 °C, 30 s
at 61 °C and 1 min at 72 °C, and a final extension of 10
min at 72 °C. PCR products (528 bp allele »L« and 482 bp
allele »S«) were separated on 2% agarose gel.
PCR for MAOA polymorphism was performed in a to-
tal volume of 15 mL containing 1.5 mM MgCl2, 0.8 mM
dNTP mix, 0.4 mM primers (forward 5’-ACAGCCTGA-
CCGTGGAGAAG-3’, reverse 5’-GAACGGACGCTCCAT-
TCGGA-3’), 0.55 U Taq polymerase, and 200 ng template.
Cycling conditions consisted of a 2-min denaturation at
95 °C, followed by 35 cycles of 30 s at 95 °C, 30 s at 61 °C
and 40 s at 72 °C, and a final extension of 7 min at 72 °C.
PCR products (306 bp allele »3« and 336 bp allele »4«)
were separated on 3% agarose gel.
PCR for TPH polymorphism was performed in a total
volume of 15 mL containing 2.0 mM MgCl2, 0.8 mM
dNTP mix, 0.5 mM primers (forward 5’-TTCAGATCCC-
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TTCTATACCCCAGA-3’, reverse 5’-GGACATGACCTAA-
GAGTTCAGGCA-3’), 0.55 U Taq polymerase, and 150 ng
template. Cycling conditions consisted of a 3-min dena-
turation at 94 °C, followed by 35 cycles of 30 s at 94 °C, 30
s at 58 °C and 40 s at 72 °C, and a final extension of 10
min at 72 °C. 5 mL of PCR products were digested with 5 U
of FspBI (Fermentas, USA) in a total volume of 20 mL
overnight. The obtained fragments (uncut allele »a« of
848 bp, and cut allele »c« of 597 bp and 251 bp) were sep-
arated on 1.2% agarose gel.
PCR for 5HT2Ar polymorphism was performed in a to-
tal volume of 15 mL containing 1.5 mM MgCl2, 0.8 mM
dNTP mix, 0.5 mM primers (forward 5’-AACCAACTTA-
TTTCCTACCAC-3’, reverse 5’-AAGCTGCAAGGTAGC-
AACAGC-3’), 0.55 U Taq polymerase, and 150 ng tem-
plate. Cycling conditions consisted of a 5-min denatura-
tion at 94 °C, followed by 30 cycles of 30 s at 94 °C, 30 s at
60 °C and 45 s at 72 °C, and a final extension of 10 min at
72 °C. 5 mL of PCR products were digested with 5 U of
MspI (Fermentas, USA) in a total volume of 20 mL over-
night. The obtained fragments (uncut allele »A« of 468
bp, and cut allele »G« of 224 bp and 244 bp) were sepa-
rated on 2% agarose gel.
Data were processed by the use of GraphPad InStat
3.01 software. Normality of distributions of the mea-
sured parameters was tested by Kolmogorov/Smirnov
test, while the equality of SDs was tested by Bartlett’s
test. Mean PSL values were compared among different
genotypes using unpaired t-test or one-way analysis of
variance (ANOVA). Values of the parameters that were
not normally distributed or that differed significantly in
their SDs were log transformed prior to ANOVA. The
level of significance was set to 0.05. Values in the text
were expressed as means ± standard deviations (X±SD).
Results
The mean PSL value of the integral sample of autistic
subjects was 74.0±33.8 ng/mL (the reported PSL values
for Croatian21 and white American22 control subjects
were 59.2±16.2 ng/mL and 68±17 ng/mL, respectively).
No significant effects of gender (F(1,62)=0.13, p=0.72),
and therapy (F(3,62)=0.62, p=0.60) on this parameter, nor
its correlation with age (r=–0.032, p=0.799) was ob-
served.
Genotypes of the four investigated polymorphisms,
with the corresponding mean PSL values, are presented
in Table 1.
SS and LL homozygotes of the 5HTt-LPR polymor-
phism displayed similar mean PSL values (69.8±24.9
ng/mL and 67.8±25.4 ng/mL, respectively), while the mean
value of LS heterozygotes was somewhat higher (81.7
±42.5 ng/mL). One subject carried 18-repeat extra-large
(XL) allele (genotype XLL) and was not included in the
statistical analysis. One-way ANOVA of the logarith-
mically transformed data did not show significant influ-
ence of this polymorphism on PSL values (F(2,61)=0.87,
p=0.71).
Similarly, polymorphism –1438 AG of the 5HT2Ar
gene did not significantly affect platelet 5HT concentra-
tions in the investigated sample (F(2,62)=0.90, p=0.15),
mean values for AA, AG and GG genotypes being 60.0
±12.2 ng/mL, 81.5±42.9 ng/mL and 69.7±24.7 ng/mL, re-
spectively.
Significant effect on the platelet serotonin level was
found for the a218c polymorphism of the tryptophan hy-
droxylase gene (F(2,62)=3.37, p=0.04). While the mean
PSL values of individuals with aa and ac genotypes were
almost identical (65.4±26.7 ng/mL and 65.4±22.8 ng/mL,
respectively), the mean platelet serotonin concentration
was about 25% higher in subjects homozygous for the al-
lele c (87.2±42.1 ng/mL).
Since the gene for MAOA is located on chromosome X,
only females can be homozygotes or heterozygotes for
the investigated polymorphism, while the males are al-
lele 3- or allele 4-hemizygotes. Mean PSL value of the
three female 3/3 homozygotes were 41.0±21.7 ng/mL, of
the four 3/4 heterozygotes were 67.3±36.0 ng/mL and of
the seven 4/4 homozygotes were 87.4±25.6 ng/mL. One
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TABLE 1
INFLUENCE OF THE GENOTYPES OF 5HT-RELATED GENES ON THE PLATELET SEROTONIN LEVEL (PSL) IN AUTISTIC SAMPLE










































subject carried allele with 4.5 repeats (genotype 4/4.5)
and was not included in the analysis. Mean values of the
male 3/0 and 4/0 hemizygotes were 65.5±23.2 ng/mL and
79.8±39.3 ng/mL, respectively. Since MAOA seems to be
expressed from only one of the two alleles in female
cells23, 3/3 homozygotes functionally correspond to the
male 3/0 hemizygotes, while 4/4 homozygotes correspond
to the male 4/0 hemizygotes. Heterozygotes are uninfor-
mative since they cannot be functionally grouped as ex-
pressing either of the alleles. When we compared the
mean platelet 5HT concentrations of the subjects carry-
ing 3/3 and 3/0 genotypes (61.8±24.2 ng/mL) to those of
the subjects carrying 4/4 and 4/0 genotypes (81.0±36.6
ng/mL), we observed significantly higher value, of about
25%, in the latter group (t=2.43, 56 df, p<0.02).
We further investigated whether the polymorphisms
a218c TPH and uVNTR MAOA, that influenced the level
of platelet serotonin, had a combined effect on platelet
5HT concentrations. We considered TPH-cc and MAOA-
-4 as »high 5HT« genotypes, and grouped subjects ac-
cording to the number of »high 5HT« genotypes (none –
neither »cc« nor »4«, one – either »cc« or »4«, and two –
both »cc« and »4«). We have observed a significant differ-
ence in the mean 5HT levels among the three groups
(F(2,57)=6.175, p<0.004, one-way ANOVA), with a clear
dose-effect. There was an increase in the mean 5HT lev-
els with the increase in the number of »high 5HT« geno-
types (F(1,57)=12.08, p=0.001, post-ANOVA test for lin-
ear trend), mean values being 57.8±25.8 ng/mL, 69.4±20.1
ng/mL, and 94.2±46.6 ng/mL, respectively (Figure 1).
Discussion
In this study, we have investigated the influence of
5HT-related gene polymorphisms on the platelet seroto-
nin level in an ethnically homogenous group of 63 sub-
jects rather severely affected with autism (mean CARS
score of 42.2±8.4). Relatively high percentage of medi-
cated subjects (60%) and a wide range of age (4-39 years)
might have affected the reliability of the PSL measure-
ments and represent the limitations of our sample. How-
ever, regarding the first, subjects receiving SSRI which
directly influence platelet 5HT concentrations were not
included in the study. Other medication not directly act-
ing on 5HT system did not seem to have any effect on the
measured PSL values, what is in line with the observa-
tions reported by Mulder et al.24 and with our observa-
tions from the previous study21. Regarding the second,
although some authors suggested the effect of puberty on
platelet 5HT levels of autistic individuals22, the mean
PSL values of 16 pre-pubertal children (69.1±19.8 ng/mL)
and 47 adults (75.7±37.4 ng/mL) in our sample did not
significantly differ (t=0.166, p=0.869, 48 df, Welch’s cor-
rected t-test) what allowed for the joint analysis of the
data.
Significant correlations between the platelet seroto-
nin level and the platelet serotonin uptake have been re-
ported in a group of autistic children25 and adults26. How-
ever, we have not found a significant effect of the 5HTt-
LPR genotypes on the platelet 5HT concentrations, what
is in line with the previously reported findings on autistic
subjects25,27–29. Therefore, it could be assumed that even if
the 5HT transporter gene is involved in development of
hyperserotonemia in autistic individuals, the mechanism
of its action does not likely include the mentioned poly-
morphism. Indeed, 5HTt-LPR represents one of the most
studied polymorphisms in autism, but the equal repre-
sentation of the studies associating allele S, allele L, or
neither of the alleles with autistic symptoms30 makes its
role in autism far from understood.
Receptor binding studies suggested a decreased ex-
pression of 5HT2A receptor on the platelets of autistic
subjects31 and their hyperserotonemic first-degree rela-
tives26, what made it an interesting candidate gene for
the association studies in autism. However, the only
study of association of the –1483AG 5HT2Ar polymor-
phism with autism, conducted so far, did not reveal pref-
erential transmission of either of the alleles from hetero-
zygous parents to the affected offspring32. In our study,
platelet 5HT concentrations did not differ among indi-
viduals carrying different –1483AG 5HT2Ar genotypes,
suggesting the lack of the involvement of this polymor-
phism in the development of hyperserotonemia.
The enzyme TPH1 regulates the rate of 5HT synthesis
in the periphery, but is also shown to be expressed in the
fetal brain, possibly regulating the development of 5HT
neurons33. So far, only one study testing the association of
a218c TPH polymorphism with autistic disorder has been
reported, with negative results34. We have found a signifi-
cant effect of the mentioned polymorphism on the 5HT
concentrations in platelets of autistic individuals, subjects
with the two »c« alleles having higher PSL values than the
subjects with the other two genotypes. Although func-
tional variants affecting TPH expression have not yet
been identified, our finding indicates that a218c SNP, or
some other nearby polymorphism, might affect the ex-
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Fig. 1. The effect of the number of »high 5HT« genotypes on the
platelet serotonin level (PSL) in autistic subjects. Genotype »cc« of
a218c TPH and genotype »4« of uVNTR MAOA were considered
as »high 5HT« genotypes. 0 – no »high 5HT« genotypes (subjects
containing neither »cc«, nor »4«, N=13), 1 – »high 5HT« genotype
at one locus (subjects containing either »cc«, or »4«, N=27), 2 –
»high 5HT« genotypes at both loci (subjects containing both, »cc«
and »4«, N=18). Results are presented as XSEM, **p=0.001, post-
-ANOVA test for linear trend).
pression of Tph1 gene, and implicates the role of TPH1 in
the development of hyperserotonemia.
Due to its role in metabolizing serotonin and catechol-
amines, as well as to its location on the chromosome X
(autism being a predominantly male disorder), MAOA
gene has also attracted interest as a potential candidate
gene in autism. Although the two reported family-based
association studies did not find preferential transmission
of either of the uVNTR MAOA alleles, both studies re-
vealed a significant effect of the mentioned polymor-
phism on IQ of the autistic probands35,36. We have found
significantly higher mean PSL values in a group of sub-
jects carrying »genotype 4« in comparison to those carry-
ing »genotype 3«, what indicates the involvement of this
functional polymorphism in the development of hyper-
serotonemia.
Finally, when TPH-cc and MAOA-4 were considered
as »high 5HT« genotypes, a significant increase in the
mean 5HT concentrations was observed with the in-
crease in the number of »high 5HT« genotypes. The
mean PSL value of the group having both, »cc« and »4«
genotypes was considerably increased and in the range of
previously determined hyperserotonemia21. The obser-
ved effect would remain significant even if we would cor-
rect the level of significance to 0.01 (due to the multiple
testing of four genotypes and one combination) what
points to the possible synergistic effect of the two genes
in regulation of the peripheral 5HT levels.
Since the discovery of hyperserotonemia in autism,
there has been a debate over what causes the elevated
5HT levels in blood – increased concentrations of plasma
free 5HT, increased accumulation of 5HT in platelets, or
a combination of both37,38. In our sample, we have ob-
served a weak individual and a stronger combined influ-
ence of a218c TPH and uVNTR MAOA genotypes on
5HT levels in platelets of autistic subjects. Although the
functionalities of the studied polymorphisms remain to
be clarified, the obtained results indicate that the genes
regulating 5HT synthesis/degradation rate (TPH and
MAOA) rather than the genes regulating 5HT transfer in
and out of platelets (5HTt and 5HT2Ar) might be in-
volved in dysregulation of the peripheral 5HT homeosta-
sis, and suggest their potential role in development of au-
tistic disorder. Before drawing any conclusions, we have
to check the influence of the investigated genotypes on
PSL in a control sample and test the association of the
corresponding genes with autistic disorder, what repre-
sents the objects of our future studies.
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HIPERSEROTONINEMIJA U AUTIZMU: MOGU]A ULOGA INA^ICA GENA
VEZANIH UZ 5HT SUSTAV
S A @ E T A K
U dijelu autisti~nih pacijenata uo~ena je povi{ena razina trombocitnog serotonina (engl. platelet serotonin level,
PSL). Kao mogu}i uzroci spominju se poja~ana sinteza serotonina (5HT) pomo}u enzima triptofan-hidroksilaze (TPH),
poja~ani unos serotonina u trombocite putem 5HT prijenosnika (5HTt), smanjeno otpu{tanje serotonina iz trombocita
preko 5HT2A receptora (5HT2Ar) i smanjena razgradnja serotonina pomo}u enzima monoamin-oksidaze (MAOA). U
ovom radu istra`en je utjecaj alela gena, koji kodiraju spomenute elemente 5HT sustava, na PSL u 63 autisti~ne osobe.
Dok genotipovi 5HTt-LPR i -1438AG 5HT2Ar nisu zna~ajno utjecali na PSL, osobe s genotipom »cc« polimorfizma a218c
TPH i osobe s genotipom »4« polimorfizma uVNTR MAOA imale su zna~ajno povi{eni PSL. Kada smo genotipove
TPH-cc i MAOA-4 ozna~ili kao »genotipove s visokim 5HT«, uo~ili smo zna~ajan porast PSL s porastom broja »geno-
tipova s visokim 5HT«. To upu}uje na mogu}i sinergisti~ki u~inak gena koji reguliraju sintezu/degradaciju serotonina
na poreme}aj regulacije periferne 5HT-homeostaze u autisti~nih osoba.
